CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
with the purpose to better the lives of people impacted by kidney
disease, granted eight newly-hired employees options to purchase an
aggregate of 49,000 shares of Akebia's common stock on December 31, 2021, as inducements material to
each such employee's entering into employment with Akebia. The
options were granted in accordance with Nasdaq Listing Rule
5635(c)(4).
The options have an exercise price of $2.26 per share, which is equal to the closing
price of Akebia's common stock on the grant date. Each stock option
vests over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with the Akebia. Each stock option has
a 10-year term and is subject to the terms and conditions of
Akebia's Inducement Award Program and a stock option agreement
covering the grant.
About Akebia Therapeutics
Akebia Therapeutics,
Inc. is a fully integrated biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease.
Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which
does not form a part of this release.
Akebia Therapeutics Contact
Mercedes
Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301453901.html
SOURCE Akebia Therapeutics